Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co EBITDA per Employee

The EBITDA per Employee of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 17, 2026 is -297,218.55 CNY. In the previous year, EBITDA per Employee was -211,270.85 CNY — a change of 40.68% (lower).

EBITDA per Employee

-297,218.55CNY

YoY

40.68%

Last updated:

EBITDA per Employee of Tibet Duo Rui Pharmaceutical Co is 2025 -297,218.55 CNY. EBITDA per Employee of Tibet Duo Rui Pharmaceutical Co was 2024 -211,270.85 CNY. It decreases by 40.68% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
177,461.32 CNY
Jan 1, 2019
284,094.78 CNY
Jan 1, 2020
359,235.31 CNY
Jan 1, 2021
271,510.69 CNY
Jan 1, 2022
90,219.02 CNY
Jan 1, 2023
72,408.25 CNY
Jan 1, 2024
-211,270.85 CNY
Jan 1, 2025
-297,218.55 CNY
The Tibet Duo Rui Pharmaceutical Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-297,218.55CNY+40.68%
-211,270.85CNY-391.78%
72,408.25CNY-19.74%
90,219.02CNY-66.77%
271,510.69CNY-24.42%
359,235.31CNY+26.45%
284,094.78CNY+60.09%
177,461.32CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co Ltd is a pharmaceutical company based in Wuhan, China, operating within the healthcare sector. The company focuses on the research, development, manufacturing, and sale of chemical preparations and their raw materials. It went public on the Shenzhen Stock Exchange on September 29, 2021, with ticker 301075.SZ and ISIN CNE100004RW5. The company employs 318 full-time staff and is headquartered in Wuhan, Hubei. Its core product is sodium acetate ringer injection, used for replenishing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection. The company's website is http://www.duoruiyy.com/. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

EBITDA per Employee of Tibet Duo Rui Pharmaceutical Co is -297,218.55 CNY in 2025.

EBITDA per Employee of Tibet Duo Rui Pharmaceutical Co changed from -211,270.85 CNY to -297,218.55 CNY, representing a 40.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Tibet Duo Rui Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Tibet Duo Rui Pharmaceutical Co

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Tibet Duo Rui Pharmaceutical Co